Organized by World Congress on Controversies in Obstetrics,Gynecology & Infertility (COGI) and West China Second University Hospital, from May 13 to 15, 2016 China HPV Forum was successfully held in Chengdu, Sichuan province. The themes of this forum were focused on HPV diagnosis and screening, HPV vaccination, and clinical treatment of gynecologic malignancies. More than 20 well-known scientists and doctors from China and abroad shared the latest news and discoveries, and the forum attracted more than 400 participants. Ideas and suggestions were presented in the field of cervical cancer prevention programs for public health policy makers.
In the forum, the former president of the International Papillomavirus Society, Professor Thomas Broker, delivered a presentation on ‘Clinical Diagnosis of Human Papillomaviruses’. “Hybribio has developed an excellent system to diagnose different types of HPV. Their approach can quickly diagnose multiple HPV types infections. With two technological platforms – self-patented flow-through diagnostic platform, and the real-time PCR diagnostic platform, Hybribio has established a mature and complete detection system, satisfying needs of different customers. Moreover, by applying clinical diagnosis and conducting large-scale screening, Hybribio has promoted academic research in Cervical Cancer and public HPV screening in China.”
As one of the leading in-vitro diagnostic (IVD) companies in China, and a pioneer and promoter of Cervical Cancer Screening, Hybribio has carried out HPV screening using new technology for civil servants and females living in rural areas in Guangdong, Xiameng, Shanghai, Tibet, Qinghai, Shandong, Daqing, and Hunan. In 2011, Hybribio started collaborating with the Ministry of Health in China to establish the very first HPV database, and joined the China “Two Cancer screening” project.
At the end of the forum, Dr. Broker accepted an interview with China Obstetrics and Gynecology Network (China-OBGYN) on topics of HPV research and the important roles of education and public policies in HPV screening.
Here is a full interview transcripts and video.